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Remote ischaemic preconditioning (RIPC) is a phenomenon whereby brief episodes of non-lethal
ischaemia in one organ or tissue can render a distant organ or tissue resistant to subsequent longer
ischaemic insults. It represents an exciting perioperative risk reduction strategy as it allows car-
dioprotection (and organ protection in general) from injuries that are caused by multiple mechanisms.
Several proof of concept studies show beneﬁts in cardiovascular interventions and in a variety of other
procedures. However convincing and consistent evidence of beneﬁts in patient important outcomes is
lacking but may emerge with the completion of large scale studies. This article aims to provide a concise
review of the origins and concepts of RIPC. It will revisit the biological theories of RIPC and the clinical
applications thus far. The article concludes by discussing the current status of multi-centre cardiovas-
cular RIPC research and the future challenges that investigators must overcome.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction to ischaemic preconditioning and remote
ischaemic preconditioning
Coronary artery disease (CAD) is a major cause of morbidity and
mortality worldwide and its prevalence is increasing [1]. There is
increased perioperative risk when patients have CAD [2] and
furthermore the risk proﬁle of those who are undergoing coronary
surgery is worsening [3]. Given that an estimated 234 million
surgical procedures are performed annually worldwide [4], the
global burden of perioperative cardiac disease is increasing andaduate Entry Medical School,
).
by Elsevier Ltd. All rights reservedtherefore it is crucial that efforts are made to reduce perioperative
risk for those with CAD.
Cardioprotection refers to a wide range of strategies that aim to
reduce perioperative cardiac risk. The common goal of car-
dioprotective techniques is the initiation of endogenous mecha-
nisms that can reduce the effects of myocardial ischaemia-
reperfusion injury [5]. To date, several strategies have been used
to reduce perioperative cardiac risk in humans: risk assessment,
prophylactic revascularisation, pharmacological cardioprotection
and myocardial conditioning techniques. Myocardial conditioning
is a broad concept that refers to both direct and remote ischaemic
preconditioning, perconditioning and postconditioning. Unfortu-
nately, not all of these risk reduction strategies have had success.
Perioperative cardiac risk assessment is theoretically attractive as it
identiﬁes patients who need optimisation of comorbidities prior to
elective surgery but hard evidence for its effectiveness is lacking.
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been disappointing [5] with the exception of using beta blockade
for high risk procedures [2]. Prophylactic coronary revascularisa-
tion was shown to be often ineffective [7e10] and is only
occasionally recommended [11,12]. However, there have been
convincing preliminary results in relation to some of the myocar-
dial conditioning techniques.
Ischaemic preconditioning (IPC) is a phenomenonwhereby brief
periods of ischaemia in an organ or tissue can confer resistance
against subsequent more sustained ischaemic insults [13]. This
counterintuitive idea was ﬁrst demonstrated in a canine model in
1986 e Murry et al. found that, following sustained coronary oc-
clusion, myocardial infarcts were smaller in dogs that had been
preconditioned when compared with dogs who did not undergo
preconditioning [14]. The preconditioning stimulus used was a
series of intermittent short duration coronary occlusions. Since
then, there have been several proof of concept trials of IPC in hu-
man cardiothoracic surgery and meta-analysis has found evidence
of beneﬁts in terms of reductions in arrhythmia rates, inotrope
requirements and intensive care unit length of stay [15]. Evidence is
lacking regarding the effects of IPC on harder clinical outcomes
such as MI and mortality rates. Unfortunately, as IPC involves
directly interfering with coronary blood ﬂow (giving rise to
ischaemia and the possibility of causing plaque rupture), the po-
tential for widespread use is limitede its only practical role is likely
to remain in elective cardiac surgery or elective percutaneous
coronary intervention (PCI).
Subsequently, evidence conﬁrmed that episodic intermittent
ischaemia of distant tissues can induce cardioprotection e this
became known as remote ischaemic preconditioning (RIPC). It was
ﬁrst demonstrated in 1993 when Przyklenk et al. showed that
applying a preconditioning stimulus to the circumﬂex coronary
artery in dogs resulted in smaller infarcts in the left anterior
descending coronary artery (LAD) distribution following LAD oc-
clusion [16]. Consequent studies found that animal skeletal muscle
[17,18], renal [19] and mesenteric [20] ischaemia had attenuating
effects on induced myocardial infarct sizes and that tourniquet
induced leg ischaemia reduced reperfusion arrhythmias [21]. In
humans, it is unlikely that transient renal or mesenteric ischaemia
can become a viable cardioprotective mechanism due to the risks
inherent in the application of the stimulus. However, as tourniquet
induced limb ischaemia has an attractive risk proﬁle, there have
been multiple small trials in humans undergoing major cardio-
vascular surgery and PCI using cuff induced limb ischaemia as the
preconditioning stimulus. Meta-analyses of these trials have
consistently shown biochemical evidence of reduced myocardial
injury although ﬁrm clinical outcomes data are lacking [22e29].
Notably a recent meta-analysis on RIPC in PCI found a beneﬁt in
terms of reduced incidence of periprocedural myocardial infarction
[30]. The remainder of this article focuses on the underlying
mechanisms of RIPC, its current status and uncertainties and views
on future RIPC research directions.Fig. 1. Proposed mechanisms of remote ischaemic preconditioning.2. Methods used in this review
Literature published in English from 1st January 1986 to 30th
January 2014 on ischaemic preconditioning and remote ischaemic
preconditioning in surgery was obtained by electronic search of
Medline. The search strategy: ([ischaemic preconditioning OR
ischemic preconditioning OR remote ischaemic preconditioning OR
remote ischemic preconditioning] AND surgery) yielded 2742
studies. Relevant studies were examined by 1 author (DH) and
additional articles were identiﬁed by cross-referencing and citation
mapping. The literature obtained formed the basis of the article.3. Underlying mechanisms of RIPC
Despite compelling evidence of reduced infarct sizes in animal
models and reduced biochemical evidence of myocardial injury in
humans, the exact mechanism underlying cardioprotection via
RIPC remains unclear. Several theories exist although none of these
has been fully accepted e it is likely that no single mechanism is
uniquely responsible but rather that several complementary
pathways exist [13]. Proposed mechanistic components are initia-
tion via a trigger at the site of the ischaemic stimulus, communi-
cation between the remote site and the myocardium and lastly the
induction of cardioprotection at the heart (Fig. 1) [31]. Evidence
suggests that IPC, RIPC and the postconditioning techniques share
common mechanistic components [13,31].
Proposed remote trigger molecules include adenosine, brady-
kinin, opioids, endocannabinoids and others while the ﬁnal effect is
thought to culminate in a strong cardioprotective and antiapoptotic
response in the heart [13,31]. Evidence implicates prevention of
opening of the mitochondrial permeability transition pore (mPTP)
in the ﬁnal antiapoptotic step e opening of the mPTP during
myocardial reperfusion is thought to initiate programmed cell
death via cellular energy depletion [32]. Pharmacologically pre-
venting mPTP closure has been shown to dramatically reduce
infarct size in animal studies [32] and in humans mPTP closure
inhibition with ciclosporin was shown to reduce infarct size in a
small study [33].
Neural, humoral and systemic communication theories have
been suggested [13]. The neural hypothesis proposes that remote
neurotransmitter release activates a neural link to the myocardium.
Support for this comes from studies that found that the ganglion
blocker hexamethonium attenuated the preconditioning effect
[20,34]. The humoral hypothesis suggests that circulating car-
dioprotective factors are released during remote site reperfusion
and subsequently act on the myocardium e studies have shown
that a preconditioning effect can be transferred via a blood trans-
fusion to a non-preconditioned animal [35e37]. The ﬁnal theory
proposes that preconditioning can induce a systemic anti-
inﬂammatory response with alteration of gene expression [13].
Overall, though progress in identifyingmechanistic components
has been slow, it is important that efforts to identify the mecha-
nisms continue e it may be possible to target these pathways
pharmacologically. Furthermore, more biological knowledgewould
help researchers optimise the physical preconditioning stimulus
and clarify other areas where uncertainty exists.
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humans
At this stage, much of the experimentation in humans has been
exploratory and has aimed to demonstrate “proof of concept”
rather than practicality. In general, numbers of included patients
have been small and there has been a focus on biochemical out-
comes rather than patient important outcomes. There is uncer-
tainty relating to many methodological issues and as further
studies emerge it is likely that it will be possible to determine the
optimal approaches, thereby allowing future multi-centre evalua-
tion with a focus on clinical outcomes. With further research and
increasing sample sizes, it is likely that a measure of the true effect
of RIPC on clinical outcomes will emerge.
5. RIPC in human cardiac surgery, percutaneous coronary
intervention and major vascular surgery
Clinical trials have evaluated RIPC in coronary artery bypass
graft (CABG) surgery [38e53], cardiac valvular surgery [53e56] and
congenital cardiac defect surgery in children [57e63]. Cardiac
surgery has seen considerably more proof of concept studies than
any other type of intervention; it is likely that several factors ac-
count for this. Firstly, it is probably a reﬂection of the fact that most
cardiac surgery is performed electively and is therefore suitable for
RIPC. Secondly, research on cardioprotection and initial IPC
research were dominated by cardiothoracic surgery and this
translated to interest in RIPC. A ﬁnal reason for the dominance of
cardiac surgery in RIPC research is that induced myocardial
ischaemia is often an integral component of cardiac surgery and
this makes cardioprotective strategies attractive.
Most of the cardiac surgery studies used cardiac injury bio-
markers as primary outcomes and pooling these results via meta-
analysis has conﬁrmed a statistically signiﬁcant beneﬁt at cardiac
biomarker level. This biomarker reduction is both consistent and
plausible. As there is mounting evidence for the prognostic signif-
icance of isolated cardiac biomarker elevations [64], it is likely that
RIPC may indeed have the ability to alter short and long term
prognosis for patients undergoing cardiac surgery. However, at
present the evidence for beneﬁts in patient important outcomes is
not convincing. Twometa-analyses that pooled cardiac surgery and
PCI found statistical evidence of reduced MI rates with RIPC [25,29]
but another review that excluded the PCI studies did not ﬁnd this
signiﬁcance [23]. It is likely that a more reﬁned measure of the true
effect of RIPC will emerge as international studies with larger
sample sizes are completed. Interestingly, evidence has also
emerged suggesting that RIPC may reduce the incidence of acute
kidney injury in patients undergoing cardiac surgery [44] e this
further underlines the biological plausibility of achieving organ
protection with RIPC.
Several studies have evaluated RIPC in emergency [65,66] and
elective PCI [67e72]. The results are variable e some studies
[65,66,68,70,71] found RIPC to be beneﬁcial in terms of myocardial
injury biomarker levels but other studies did not ﬁnd such a beneﬁt
[67,69]. Surprisingly, one trial found RIPC to be associated with
cardiac enzyme elevation although this trial had the limitation of a
small sample size [69]. A study on RIPC in elective PCI found that
RIPC was able to reduce the incidence of contrast induced acute
kidney injury [72]. In relation to emergency PCI, a major challenge
is timely administration of the RIPC stimulus in the setting of acute
MI e one of the studies initiated RIPC during transit [65] and
another initiated RIPC shortly before PCI commenced [66]. The
trials have shown that this difﬁculty can be overcome and that
beneﬁts are likely to exist. A meta-analysis of RIPC in PCI found
reduced incidence of periprocedural myocardial infarctionalthough there was notable clinical heterogeneity among the
studies [30]. The challenge is to evaluate clinical outcomes in an
adequately powered study. Long term clinical outcomes follow up
data is available the CRISP Stent trial [73] e interestingly, RIPC was
associated with a lower major adverse cardiac and cerebral event
rate at 6 years.
Trials have also evaluated RIPC in the setting of major vascular
surgery: open abdominal aortic aneurysm (AAA) repair [74e76],
endovascular aneurysm repair (EVAR) [77] and carotid endarter-
ectomy [78]. There were two AAA repair trials where iliac artery
cross-clamping served as the preconditioning stimulus [74,75]. The
larger of these [74] (n¼ 82) found a signiﬁcant reduction in levels of
cardiac troponin I, myocardial infarction rates and renal impair-
ment rates with the RIPC intervention and the other study (n ¼ 40)
focused on biochemical markers of renal injury and could not
conﬁrm a beneﬁt with RIPC [75]. 4 patients in the RIPC arm of this
trial developed acute lower limb ischaemia requiring operative
intervention e this has raised concerns about the suitability of iliac
cross-clamping as the preconditioning stimulus. The third AAA
RIPC study used the upper limb for the stimulus [76], considering
the negative experiences with iliac cross clamping in the prior
work. In this study (n ¼ 62) RIPC reduced markers of pulmonary
and intestinal injury and it also reduced markers of systemic in-
ﬂammatory response but there was no difference in clinical out-
comes. The study on EVAR procedures found biochemical evidence
of reduced renal injury with RIPC but no difference in renal
impairment or clinical outcomes [77]. Inﬂation of a cuff around the
thigh served as the stimulus and there were no lower limb
ischaemic events, which may suggest that non-invasive lower limb
arterial occlusion is better than arterial clamping. RIPC in carotid
endarterectomy was also evaluated [78] using a thigh tourniquet
(without lower limb adverse events) but without a demonstrable
effect of RIPC on cardiac or neurological outcomes.
Overall, the trials in major cardiovascular surgery and PCI have
had promising results. The feasibility of using RIPC in these groups
has been established and the remaining challenge is to apply RIPC
in larger studies with a focus on patient important outcomes. It
appears as though upper limb tourniquet induced ischaemia might
be the best approach for these patients given the likelihood of co-
existing chronic occlusive lower limb arterial disease and the pos-
sibility for acute ischaemia when arteries are occluded via
clamping.
6. RIPC in other types of intervention
Animal models have conﬁrmed a neuroprotective role for RIPC
and IPC e studies found that preconditioning rodents with leg
ischaemia reduced stroke size following middle cerebral artery
occlusion [79,80] and that direct rodent brain ischaemia was also
protective [81,82]. However, there are few studies on such neuro-
protection in humans. A non-signiﬁcant beneﬁt in preservation of
saccadic latency (a measure of neurologic function) was shown
with RIPC in the carotid endarterectomy study mentioned above
[78]. A study evaluating the effect of RIPC on spinal cord ischaemia-
reperfusion injury in patients undergoing cervical decompression
procedures found that RIPC reduced levels of neurological injury
biomarkers [83]. There is also some evidence for a protective effect
of direct brain ischaemia in humans e during berry aneurysm
clipping, episodic and short-lived direct brain ischaemia was
shown to have a beneﬁcial effect on local pH and blood oxygen
content [84]. A study on carotid stenting found that episodes of
neurological dysfunction induced by angioplasty balloon inﬂation
did not recur following repeated inﬂations [85], giving further
support to the idea that neuroprotection can be achieved via
conditioning.
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ﬂap microsurgery, proof of concept studies conﬁrmed that IPC and
RIPC can reduce ischaemia-reperfusion injury and improve ﬂap
outcomes [86,87]. IPC was ﬁrst shown to be effective in this area in
1992 [88] and multiple in vivo animal studies followed [86]. Limb
ischaemia was shown to be as effective as direct ﬂap ischaemia in
further animal work that followed [89,90]. Although experimental
data are promising, preconditioning has not achieved much clinical
use in plastic surgery in humans to date; reasons for this are
probably the increased operative time required and other practical
difﬁculties. It follows that randomised clinical data are lacking and
this is a target for the future.
In relation to liver surgery, IPC has been shown to reduce the
severity of ischaemic injury in murine models of hepatic ischaemia
[91,92]. However, clinical beneﬁts of IPC in human hepatectomy
surgery have not materialised. A Cochrane review of IPC in elective
liver resections found no beneﬁt with IPC other than reduced blood
transfusion requirements [93]. Another review found no clinical
beneﬁt but found that IPC reduced liver injury at biochemical level,
a ﬁnding that is of uncertain signiﬁcance [94]. Further high quality
studies are needed in this area.
7. Ongoing trials
There are several ongoing multi-centre trials investigating RIPC
in major cardiovascular surgery. We are hopeful that deﬁnitive
evidence of beneﬁts in clinical outcomes will emerge with the
completion of these trials.
The Remote Ischaemic Preconditioning for Heart Surgery study
(RIPHeart-Study) is a multi-centre clinical trial in Germany that is
currently recruiting patients who are undergoing surgery with a
need for cardiopulmonary bypass [95]. It aims to recruit 2070
adults including both high and low risk categories (high risk means
Euroscore 5) and currently recruitment is at over 1000. The
intervention comprises 4 cycles of 5 min of cuff induced upper limb
ischaemia with 5 min of reperfusion between each inﬂation.
Another key design feature is robust blinding of surgical and
anaesthetic teams, data collectors, analysis teams and the endpoint
committee. This is achieved with a sham arm e only the person
applying the intervention knows the treatment allocation.
Furthermore, a total intravenous anaesthetic regimen is being used
to eliminate the potential preconditioning effect of volatile anaes-
thetics [96]. Cardiopulmonary bypass management in the trial is
standardised [95]. The primary outcome is a composite of all-cause
mortality, non-fatal myocardial infarction, any new stroke, and/or
acute renal failure until hospital discharge (up to a maximum of 14
days after surgery). The expected control group primary event rate
for this is estimated as 12% and the investigators think that RIPC
might reduce the event rate to 8%.
The effect of remote ischemic preconditioning on clinical out-
comes in patients undergoing coronary artery bypass surgery
(ERICCA) trial is a multi-centre trial in the United Kingdom that is
currently recruiting high risk (Euroscore 5) patients who are
undergoing coronary artery bypass graft surgery ± valve surgery
[97]. The trial aims to recruit 1610 adults and it uses a similar RIPC
intervention to the RIPHeart-Study. The blinding strategy in ERICCA
is robust and uses an adjustable valve on the cuff rather than a
sham arm. In contrast to the RIPHeart-Study, volatile anaesthetic
agents may be used in ERICCA which will probably increase
external validity although it may dilute the treatment effect. The
primary outcome is a composite of cardiovascular death, non-fatal
myocardial infarction, coronary revascularisation and stroke at one
year. The control group event rate is predicted to be 20% and the
RIPC group event rate is estimated to be 14.6%. The higher event
rates reﬂect the exclusion of patients with Euroscore 5.The Renal Protection Against Ischaemia Reperfusion in Trans-
plantation (REPAIR) trial [98] is another multi-centre trial. It has
completed recruitment (406 patients randomised) and published
results are awaited. It aimed to determine the effect of RIPC on renal
function after renal transplantation using estimated glomerular
ﬁltration rate (eGFR) at one year as the primary outcome. It alsowill
report on some clinical outcomes at 2e5 years using registry follow
up. There were 4 arms in the trial e control, early RIPC, late RIPC,
combined early and late RIPC. Early RIPC was performed immedi-
ately pre-operatively and late RIPC was performed 24 h before
operations. Dual RIPC involved both. The stimulus was 3 cycles of
5 min of cuff induced arm ischaemia with 5 min reperfusion and
routine anaesthetic practices were used.
8. Uncertainties and unresolved questions
Though the potential of RIPC is great, there are many barriers
that researchers must overcome. The unanswered questions largely
fall into two categories: the mechanistic pathway and practical
application issues.
We have examined theories on the biological basis for RIPC and
IPC in a prior section of this article and it is clear that sustained
research efforts are needed. Knowledge of the involved pathways
would enhance and focus future applications of preconditioning
and might enable pharmacological initiation of preconditioning
cardioprotective pathways.
There are many methodological uncertainties for RIPC re-
searchers and it is important that efforts are made to elucidate
these in order to increase research efﬁciency and facilitate com-
parisons between studies. Firstly, the optimal preconditioning
stimulus has not been established. While undoubtedly skeletal
muscle is the most attractive tissue to use for the stimulus, there is
uncertainty regarding the optimal duration and number of
ischaemia-reperfusion cycles. Furthermore, both upper and lower
limbs are options. Theoretically, the increased muscle bulk in the
lower limb is advantageous e one cardiac surgery study found that
RIPC induced by both leg and arm ischaemia reduced myocardial
injury compared to the control group but that RIPC induced by arm
ischaemia only did not reduce myocardial injury [56]. However
there were acute ischaemic complications with invasive lower limb
arterial occlusion in one of the vascular trials mentioned above
[75]. To our knowledge, there have been no serious cuff related
lower limb or upper limb RIPC complications. Nonetheless, it is
probably reasonable for researchers to use the upper limb only as it
is rarely affected by peripheral vascular disease (PVD) and has been
successfully used in many clinical studies to date, establishing both
feasibility and efﬁcacy. In the absence of ﬁrm evidence, we propose
that researchers use 3 or 4 cycles of 5 min ischaemia with 5 min
reperfusion e there has been a tendency for negative results in a
short stimulus time [51] and in studies that used 10 min ischaemic
episodes [75,77,78].
There is also vagueness regarding the optimal target pop-
ulations for intervention with RIPC. It is worth highlighting that
RIPC induced protection is not absolute e prolonged ischaemia is
always lethal and major insults are likely to surmount any car-
dioprotection. The challenge is to focus efforts on procedures with
relatively cardiac high event rates as such patients will beneﬁt
maximally and such trials are likely to yield positive results at
feasible sample sizes.
Lastly, it is important to reiterate that future studies on RIPC in
major cardiovascular interventions should focus on patient
important outcomes. In cardiovascular surgery, beneﬁts in surro-
gate outcomes have been conﬁrmed consistently by meta-analyses
e the only way to advance is by shifting towards clinical outcomes
where conclusions are less certain.
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RIPC is a novel, cost effective and widely available protective
phenomenon that has the potential to reduce ischaemia reperfu-
sion injury in major cardiovascular interventions and inmany other
procedures. Though knowledge gaps exist, particularly in relation
to biological mechanisms and some methodological issues, RIPC
research has advanced considerably over recent years. The main
challenges for the future are to clarify the mechanistic pathways
and to demonstrate tangible beneﬁts in patient important
outcomes.
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